Strata Critical Medical (NASDAQ:SRTA) Releases Earnings Results, Misses Estimates By $0.10 EPS

Strata Critical Medical (NASDAQ:SRTA) released its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.10), FiscalAI reports. The firm had revenue of $74.08 million for the quarter. Strata Critical Medical had a negative net margin of 8.84% and a negative return on equity of 2.70%.

Here are the key takeaways from Strata Critical Medical’s conference call:

• Q3 results exceeded guidance, with revenue up 50.3% year over year to $74.1 million, adjusted EBITDA rising to $9.6 million, and record free cash flow of $8.6 million. Management reiterated 2026 revenue, adjusted EBITDA, and free-cash-flow guidance.
• The clinical segment grew 20.3% sequentially and more than 30% on a comparable year-over-year basis, even as industry transplant volumes declined seasonally. Management attributed the performance to market-share gains from its integrated organ recovery, perfusion, and logistics offering, with clinical growth expected to lead in 2027.
• Logistics revenue declined 6.9% sequentially and 3.5% year over year, pressured by seasonal transplant weakness and approximately 10% shorter industry trip distances, particularly following changes to lung-allocation rules. The company expects logistics revenue to be roughly flat sequentially in Q4, while clinical drives overall growth.
• Strata ended the quarter with $41.6 million in cash and short-term investments after receiving $15.3 million from its Passenger earnout, with another $27.5 million potentially due in early 2027. The company authorized a $20 million share repurchase while maintaining plans to accelerate acquisitions at targeted mid-single-digit valuation multiples.

Strata Critical Medical Stock Down 3.0%

Shares of SRTA stock traded down $0.16 during trading hours on Thursday, hitting $5.06. 579,811 shares of the company’s stock traded hands, compared to its average volume of 962,016. The stock’s 50 day simple moving average is $5.02 and its 200 day simple moving average is $5.20. The stock has a market cap of $447.84 million, a PE ratio of -126.55 and a beta of 2.56. Strata Critical Medical has a 12 month low of $3.95 and a 12 month high of $6.50.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Strata Critical Medical in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Insider Activity at Strata Critical Medical

In related news, Director Reginald Love sold 5,091 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $5.75, for a total value of $29,273.25. Following the sale, the director owned 146,481 shares of the company’s stock, valued at $842,265.75. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 15.50% of the company’s stock.

About Strata Critical Medical

Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.